A recent study reveals that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who stop traditional lifestyle regimens.
Research printed in a prominent health publication shows that while overweight people often shed substantial amounts of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users buying such drugs must be informed of the risk of quick rebound weight gain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a reversion to original weight in about a year and a half.
Analyzing Approaches
The research, which reviewed dozens of trials involving thousands of patients, compared the results of GLP-1 agonists with other pills.
Scientists point out that individuals who shed pounds through dieting generally have a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Fast Regain
Experts believe the mechanism of the drugs is key to understanding the heightened weight return.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 levels far above than the body's typical production might result in the body to produce less of its own natural hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement results in appetite is no longer kept in check, making overeating much more probable."
An Ongoing Disease?
The NHS suggest the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals argue that, given the high risk of relapse, the therapy is often long-term.
This opinion is reinforced by pharmaceutical companies, who note that the results "emphasize the long-term nature of obesity," comparing it to managing diseases like hypertension.
User Accounts
People who have discontinued the medication describe a powerful resurgence of hunger.
"I experienced a trigger that goes on and you become extremely hungry," recalled one woman.
This challenge is worsened if patients have not established lasting lifestyle or habit changes during therapy.
Widespread Use
Recent estimates show that millions of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is more common among women compared to males.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
In conclusion, experts caution that while these medications are potent tools for shedding pounds, they are not a magic cure and lasting health benefits likely depends on ongoing behavioural management.